Construction of an anti-inflammatory effect evaluation system
Stem cell supernatants are produced and sold by many companies, but there is no regulation, so inferior supernatants are sold at high prices. In addition, not only the supernatant, but also the cell therapy, there is no evaluation method for the effect in clinical practice, so the effect is variable even if it is administered. There are also problems such as not being able to see efficacy even in high cost.
Therefore, we will provide high-quality regenerative medicine at a lower cost by developing an efficacy evaluation system for supernatant fluid and stem cells. By incorporating this system, it can be used as an index of efficacy that cannot be measured at present, so we aim to register it as a test method and obtain a patent.